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Psychiatric genetic research has exploded in search of 
polygenic risk factors over the past decade, but because 
of the complexity and heterogeneity of mental illnesses, 
using the current understanding of the genome has not 
reached the conclusion of finding a cause for psychiatric 
disorders. Obsessive-compulsive disorder is a relatively 
common and often debilitating neuropsychiatric disorder 
that has not been the primary focus in psychiatric 
research. Clinicians and researchers who have dedicated 
to investigate the genetics of obsessive-compulsive 
disorder have detected a strong genetic involvement. This 
review will provide an update and a new perspective on 
the current understanding of the genetics of obsessive-
compulsive disorder, which includes epidemiological data, 
family and twins studies, candidate gene studies, genome-
wide association studies, copy-number variants, imaging 
genetics, epigenetics, and gene–environment interaction. 
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Introduction
Obsessive-compulsive disorder (OCD) is a chronic 
and severe neuropsychiatric disorder, affecting 1–3% 
of the overall population (Ruscio et al., 2010). It has a 
lifetime prevalence of 2.3% and 12-month prevalence 
of 1.2% (Ruscio et al., 2010) in addition to subclinical 
rates for healthy individuals and individuals with other 
psychiatric disorders ranging from 13 to 17% and 31 to 
49%, respectively (Fullana et al., 2009). OCD is char-
acterized by chronic and often debilitating symptoms 
of obsessions and compulsions (American Psychiatric 
Association, 2013). Obsessions are irrational, unwanted, 
and intrusive thoughts, images, impulses, and urges that 
generate significant distress, whereas compulsions are 
repetitive rituals and mental acts that cannot be resisted 
and are performed in order to alleviate distress (American 
Psychiatric Association, 2013).
According to the WHO, OCD is one of the top 10 lead-
ing causes of disability globally and is the fourth most 
frequently diagnosed psychiatric disorder. Therefore, 
improving public awareness in addition to optimizing 
assessment and treatment is necessary to reduce the soci-
etal burden of OCD worldwide.
Treatment of OCD consists of two main streams, psy-
chotherapy and pharmacotherapy. Cognitive behavior 
therapy (CBT) with exposure and response prevention 
is the first-line psychological treatment of OCD and ser-
otonergic antidepressants are considered to be the first-
line pharmacological treatment of OCD (Koran et al., 
2007; Katzman et al., 2014). However, response rate 
varies ranging from 40 to 60% in medication treatment 
(McDougle et al., 1993; Foa et al., 2005) and 70 to 86% 
for CBT (Foa et al., 2005). Furthermore, both treatment 
options have limitations including side effects from the 
medications, commitment time, and access for CBT 
(Sadock et al., 2007). Currently, treatment guideline to 
differentiate patients according to their response and tol-
erability to medications and CBT does not exist. Thus, 
genetic profiling coupled with new knowledge on treat-
ment outcome would provide a substantial leap in the 
management of OCD.
The underlying etiology of OCD remains largely 
unknown and improving the understanding of the bio-
logical mechanism of OCD will help guide research to 
optimize the identification of and treatment for this debil-
itating disease. Genetics has been studied extensively 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Genetics of obsessive-compulsive disorder Zai et al. 143
across psychiatric disorders and experts would agree that 
the underpinning of psychiatric disorders is at least partly 
due to polygenic effects.
Traditional genetic studies have utilized hypothe-
sis-driven candidate gene approach. Specific genes were 
chosen based on the putative biological mechanisms and 
drug targets of existing psychotropic medications. With 
advances in genomic technology and bioinformatics, the 
use of genome-wide association studies (GWAS) has sig-
nificantly increased in the past decade, which provided 
ways to investigate previously unexplored regions that 
may be of great importance in the etiology of OCD.
This review article will first provide an update on the 
heritability of OCD, followed by results from important 
human and animal candidate gene studies and GWAS 
(Burton et al., in press). Subsequently, this article will 
summarize studies on rare genetic variants, genetics 
of intermediate phenotypes including drug response 
and imaging, epigenetics in addition to gene–gene and 
gene–environment interactions (Burton et al., in press). 
Finally, this article will end with shared genetic phenom-
enon: overlap across psychiatric disorders, in light of the 
Brainstorm paper (Brainstorm et al., 2018), and future 
perspectives on the genetics of OCD.
Heritability and familiality of obsessive-compulsive 
disorder
Family studies have shown that the prevalence of OCD 
in the relatives of individuals with OCD is higher than the 
general population, 10–12% versus 1–3%, respectively 
(Nestadt et al., 2000; Pauls, 2010; Pauls et al., 2014). Twin 
studies have estimated the heritability of OCD ranging 
from 42 to 65% (Pauls et al., 2014) for OCD symptoms, 
27 to 47% for adult-onset OCD, and 45 to 65% for child-
hood-onset OCD (van Grootheest et al., 2005; Zilhao et 
al., 2019).
Candidate gene studies in humans with obsessive-
compulsive disorder
Evidence from genetic linkage and candidate gene stud-
ies has implicated the importance of several specific 
regions and genes in the pathoetiology of OCD. The 
following sections will highlight the major findings from 
human candidate gene studies of OCD.
Serotonergic system genes
The serotonergic system is one of the most extensively 
studied systems in the genetics of OCD because of the 
rationale of using selective serotonin reuptake inhibi-
tors (SSRIs) as the primary pharmacological treatment 
of OCD based on randomized clinical trials (CPA, 2006; 
Koran et al., 2007; Soomro et al., 2008; Davis et al., 2013; 
Murphy et al., 2013; Katzman et al., 2014; Bandelow et 
al., 2016). The widely known mechanism of action of 
SSRIs is that they increase the level of serotonin in the 
synaptic cleft in order to bind to postsynaptic receptors, 
which lead to the inhibition of its reuptake into the pre-
synaptic cells. The target of SSRIs, the serotonin trans-
porter coded by the SLC6A4 gene, has consistently been 
reported to be associated with OCD (Taylor, 2013; Brem 
et al., 2014; Walitza et al., 2014; Taylor, 2016). These stud-
ies have detected the L
A
 allele of the single nucleotide 
polymorphism (SNP), rs25531, within the serotonin 
transporter-linked polymorphic region (5-HTTLPR) of 
this gene increases the risk for OCD. The serotonin 2A 
receptor (HTR2A) gene is another commonly studied 
candidate gene for OCD and based on the most recent 
meta-analysis (Taylor, 2013), it showed a nominally signif-
icant result for the rs6311 SNP [odds ratio (OR) = 1.219; 
95% confidence interval (CI), 1.037–1.433; P = 0.003]. In 
addition to the most consistent findings for 5-HTTLPR 
and HTR2A rs6311 in OCD (Sinopoli et al., 2017), mixed 
results of other serotonergic genes with OCD, including 
monoamine oxidase A (MAOA), tryptophan hydroxylase 
(TPH1 and 2), and serotonin 1D-beta receptor (HTR1B), 
have been reported, which require further replication 
(Walitza et al., 2004; Liu et al., 2013; Taylor, 2013; Brem et 
al., 2014; Di Nocera et al., 2014; Mas et al., 2014; Sampaio 
et al., 2015).
Glutamatergic system genes
Evidence has implicated the alteration of the glutamate 
system as part of the neuropathophysiological etiology of 
OCD, specifically with a disturbance in the cortico-stri-
ato-thalamo-cortical (CSTC) circuit (Pauls et al., 2014). 
Converging evidence from animal and human studies 
supports abnormal activation within this circuit, lead-
ing to hyperactivation of the orbitofrontal-subcortical 
pathway, which in turn mediates exaggerated concerns 
related to danger, harm, symmetry, and contamination, 
as seen in individuals suffering from OCD (Pauls et al., 
2014). Additional rationale of the involvement of the glu-
tamatergic system comes from magnetic resonance spec-
troscopy (MRS) studies, knock-out mouse models, and 
clinical trials of glutamatergic agents (Wu et al., 2012). 
The most studied glutamate gene is the neuronal glu-
tamate transporter (SLC1A1) gene and although a gen-
eral meta-analysis reported a nonsignificant association 
(Taylor, 2013), an in-depth meta-analysis by Stewart et 
al. (2013s) showed a moderately significant finding for 
SNPs across the 3′ region of the SLC1A1 gene includ-
ing rs301443 (P = 0.046) and rs12682897 (P = 0.012) when 
controlled for gender. Dickel et al. (2006) also showed 
an association of rs378041 in SLC1A1 with early-onset 
OCD in males, which was replicated by Stewart et al. 
(2007a). Nonetheless, a recent study did not support a 
role of SLC1A1 in the risk of OCD (Kim et al., 2018) while 
others reported positive association in males [rs2228622 
(Abdolhosseinzadeh et al., 2019); rs301443 (de Salles 
Andrade et al., 2019)]. Additional glutamate system 
genes that have been examined include: the glutamate 
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receptor, ionotropic N-methyl D-aspartate (NMDA) 2B 
(GRIN2B) gene, which has also been reported to have a 
significant association with the diagnosis of OCD (Arnold 
et al., 2004); glutamate related synapse (SAPAP/DLGAP 
family); and NMDA receptor genes (GRIN and GRIK 
family) with mixed findings. Although no sex-specific 
SNP associations were reported, Khramtsova et al. (2018) 
found two significant gene-based associations in the glu-
tamate ionotropic receptor delta type subunit 2 (GRID2) 
and G protein-coupled receptor 135 (GPR135) in females 
but no in males.
Dopaminergic system genes
The dopaminergic system has been examined in OCD 
due to the effects of antipsychotics as adjunct medica-
tions to antidepressants for the treatment of OCD (Pauls 
et al., 2014). Additional studies using animal models, 
neuroimaging, and neurochemical approaches also impli-
cate dopaminergic dysfunction in the pathophysiol-
ogy of OCD (Koo et al., 2010). A meta-analysis (Taylor, 
2013) showed a nominally significant finding for the 
catechol-O-methyltransferase (COMT) rs4680 marker 
(OR = 1.200, P = 0.010). COMT is involved in the turnover 
of monoamines in the brain. Five studies found that the 
low activity Met allele of the COMT rs4680 (Val158Met) 
SNP was overrepresented in males with OCD when 
compared with healthy males (Melo-Felippe et al., 2016). 
This was later confirmed to be disorder specific in males 
with OCD when comparing to other psychiatric disorders 
(Taylor, 2016). Inconsistent findings of the involvement 
of other dopaminergic system genes suggest that further 
investigations are warranted in significantly larger and 
well-characterized samples of OCD.
Other genes
Several additional systems have been investigated in 
the genetics of OCD and they include the GABAergic 
system, neurotrophic system, and neuron-related genes. 
GABA-related genes have been studied with inconsistent 
and nonreplicated results (Taylor, 2013). Similar lack of 
support was reported for the brain-derived neurotrophic 
factor (BDNF) gene in OCD including the most studied 
Val66Met (rs6265) variant (Zai et al., 2015), in addition to 
genes related to neuroplasticity (Taylor, 2013). A recent 
study reported an overrepresentation of the BDNF rs6265 
(Val-66-Met) Met allele in healthy individuals when com-
pared with individuals with OCD and this allele was also 
significantly associated with lower contamination/wash-
ing symptom dimension score (Taj et al., 2018). Neuronal 
growth-related genes including the myelin-oligodendro-
cyte glycoprotein (MOG) (Zai et al., 2004) and oligoden-
drocyte lineage transcription factor 2 (OLIG2) (Stewart et 
al., 2007b; Zhang et al., 2015b) genes showed promising 
findings in OCD; however, these associations needs to be 
further confirmed and replicated.
Candidate genes in obsessive-compulsive disorder 
identified through animal studies
Abnormalities within the CSTC circuitry, which involves 
the orbitofrontal cortex (OFC), anterior cingulate cor-
tex, and striatum, have been consistently reported in 
OCD (Saxena and Rauch, 2000; Ting and Feng, 2011; 
Monteiro and Feng, 2016). Thus, novel animal models of 
OCD that can manipulate this circuit have been devel-
oped and used to further our understanding of the eti-
ology of OCD. Four genetic animal models have been 
reported: SAP90/PSD95-associated protein 3 (SAPAP3) 
null mice, SLIT and NRTK-like family, member 5 gene 
(SLITRK5) null mice, homeobox B8 (HOXB8) null mice, 
and SLC1A1/EAAC1 null mice, in addition to a recent 
multispecies study in OCD.
SAPAP3 encodes a protein, which is highly expressed 
in the striatum. It is involved in postsynaptic scaffold-
ing at excitatory (glutamatergic) synapses. Welch et al. 
(2007) showed that the SAPAP knock-out mice dis-
played abnormal behaviors consistent with an increase 
in anxiety and compulsive self-grooming, which were 
alleviated with repeated administration of fluoxetine. 
Three human genetic association studies later exam-
ined the role of this gene in OCD. Bienvenu et al. 
(2009) tested the association of SAPAP3 in 383 families 
with grooming disorders and reported nominally signif-
icant association with at least one grooming disorders 
but not with OCD alone. The second study sequenced 
SAPAP3 in patients with trichotillomania and OCD and 
detected significantly higher percentage of novel non-
synonymous heterozygous variants than healthy con-
trols (4.2 versus 1.1%) (Züchner et al., 2009). The third 
study investigated seven variants within SAPAP3 in 172 
patients with OCD, 45 patients with trichotillomania, 
and 153 healthy controls (Boardman et al., 2011) and 
observed a nominal association between rs11583978 and 
trichotillomania, which did not survive testing for mul-
tiple comparison. The authors also detected significant 
association between earlier age at onset of OCD and the 
A-T-A-T (rs11583978-rs7541937-rs6662980-rs4652867) 
haplotype when compared with the C-G-G-G haplo-
type, implicating this gene in the development of early 
onset OCD.
SLITRK5 encodes for a protein that regulates neur-
ite outgrowth, which is important in neuronal survival. 
Shmelkov et al. (2010) reported that the SLITRK5 knock-
out mice showed obsessive-compulsive-like behaviors 
including excessive self-grooming and increased anxiety 
in the open maze test, which were reversed using chronic 
fluoxetine treatment. SLITRK5 is widely expressed in 
the central nervous system and preferential increase in 
neuronal activity in the OFC of the SLITRK5 null mice 
was observed, which is consistent with human OCD 
functional imaging findings (Grünblatt et al., 2014).
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HOXB8 encodes a nuclear protein that functions as a 
sequence-specific transcription factor, which has an 
important role in establishing body patterning during 
embryonic development. HOXB8 knockout mice were 
observed to develop compulsive self-grooming behavior 
and fur loss in addition to excessive grooming of wildtype 
(normal) caged-mice (Greer and Capecchi, 2002).
The fourth animal model has shown the greatest genetic 
contribution in OCD, which is consistent with human 
genetic findings. The neuronal excitatory amino acid car-
rier 1 (EAAC1), which is encoded by SLC1A1, plays a vital 
function in transporting glutamate and regulating post-
synaptic action of glutamate; it is essential in maintaining 
extracellular glutamate concentrations below oxidative 
stress and toxic levels (Aoyama et al., 2006; Scimemi et 
al., 2009). Thirty percentage of EAAC1 null mice were 
found to have increased aggression in addition to exces-
sive self-grooming and fur loss (Aoyama et al., 2006), 
which was reduced with N-acetyl-cysteine treatment, a 
prodrug of glutathione that modulates the glutamatergic 
system (Aoyama et al., 2006; Berman et al., 2011).
A recent investigation of 592 cases of OCD and 560 con-
trols that sequenced 608 OCD candidate genes with their 
regulator elements (Noh et al., 2017) detected genome-
wide significance for the neurexin 1α gene, NRXN1, 
which encodes the synapse cell-adhesion protein, neu-
rexin 1α, a component of cortico-striatal neural path-
way. This study demonstrated the genetic overlap with 
two animal models of compulsive behavior, in excessive 
grooming mice, and the so-called canine compulsive 
behavior. However, the five genes that these investiga-
tors found to be most associated with compulsive behav-
ior in mice and dogs, including the well known SAPAP3 
model, were significantly enriched for rare variants in the 
human sample, but did not reach statistical significance.
Genome-wide association studies
There are four GWASs to date in OCD. The International 
Obsessive-Compulsive Disorder Foundation Genetics 
Collaborative (IOCDFGC) conducted the first GWAS 
(Stewart et al., 2013b), which included 1465 patients with 
Caucasian OCD, 400 trios, and 5557 controls. For the 
trio subanalysis, an SNP near the BTB domain contain-
ing 3 gene (BTBD3) reached genome-wide significance 
(P = 3.84 × 10−8). For the case-control subanalysis, several 
intronic SNPs within the discs large homolog-associated 
protein 1 (DLGAP1), a gene previously found to be asso-
ciated with OCD, also approached genome-wide signifi-
cance. However, no genome-wide significant SNPs were 
identified in the combined trio and case-control analysis. 
This first GWAS identified top SNPs that were enriched 
for frontal lobe and methylation expression quantitative 
trait loci.
The OCD Collaborative Genetics Association Study 
consortium performed the second GWAS on a sample 
of 5061 individuals including 1065 families with 1406 
patients with childhood-onset OCD, and unrelated pop-
ulation-based controls (Mattheisen et al., 2015). A marker 
mapped close to the protein tyrosine phosphatase, 
receptor type D gene (PTPRD) was found to approach 
genome-wide significance (P = 4.13 × 10–7), and loci near 
the cadherin genes, CDH9 and CDH10, were detected 
to have the next lowest P value (P = 1.76 × 10–6 and 
1.13 × 10–5).
A recent meta-analysis of the first and second GWASs 
was published with a total sample of 2688 Caucasian 
patients with OCD and 7037 ancestry-matched con-
trols (International Obsessive Compulsive Disorder 
Foundation Genetics and Studies, 2018). Although there 
was no genome-wide significant markers, the SNPs with 
the lowest P values tagged the haplotype blocks close to or 
within the cancer susceptibility 8 (CASC8/CASC11), glu-
tamate ionotropic receptor delta type subunit 2 (GRID2), 
and KIT proto-oncogene receptor tyrosine kinase (KIT) 
genes. Previously detected markers in other GWASs have 
also been detected as top SNPs in this combined GWASs 
meta-analysis: Ankyrin repeat and SOCS box contain-
ing 13 (ASB13), GRIK2, CHD20, DLGAP1, fas apoptotic 
inhibitory molecule 2 (FAIM2), PTPRD, and R-spondin 4 
(RSPO4). Gene enrichment analysis conducted from the 
results of the first two OCD GWASs yielded a molecular 
landscape that was enriched for proteins involved in syn-
aptic plasticity via regulation of postsynaptic dendritic 
spine formation through insulin-dependent signalling 
cascades (van de Vondervoort et al., 2016).
The most recent GWAS analyzed 6931 participants 
with obsessive-compulsive symptoms (OCS) from 
The Netherlands Twin Registry (NTR), which iden-
tified a genome-wide significant marker (rs8100480) 
in the BLOC-1 related complex subunit 8 (BORCS8 
or MEF2BNB) gene in addition to four significant hits 
within the myocyte enhancer factor 2B (MEF2B) fam-
ily (den Braber et al., 2016). Polygenic risk score based 
on the IOCDFGC GWAS significantly predicted OCS, 
implicating that OCS may potentially be useful in gene 
discovery for OCD.
Copy number variation in obsessive-compulsive 
disorder
Other genetic variations including copy number varia-
tions (CNVs) using cytogenetic technologies and rare 
genetic mutation using whole exome or whole genome 
sequencing techniques should be considered when 
investigating the underlying genetic risk of OCD.
Microsatellite repeat markers including SLC6A4 
5-HTTLPR and STin2 VNTR, BDNF (GT)n, DAT1 
VNTR, and DRD4 VNTR have previously been exam-
ined in the genetic basis of OCD. A meta-analysis 
comprising eight datasets examined the 5-HTTLPR 
marker and reported an overall significant result (mean 
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OR = 1.251; 99th percentile CI, 1.048–1.492; P = 0.001) 
(Taylor, 2013). This meta-analysis only investigated bial-
lelic SNPs and thus, multiallelic markers and haplotyptes 
for genetic association with OCD were not included.
To date, several studies have examined CNVs in OCD. 
Walitza et al. (2012) investigated the rs6311 marker in 
HTR2A in 136 pediatric individuals with OCD and a 
CNV within the HTR2A promoter region was significantly 
associated with the risk for OCD, its onset and severity 
(Taylor, 2016). A study conducted by the IOCDFGC group 
(McGrath et al., 2014) did not detect an increase in global 
CNV burden in OCD but the findings implicated a 3.3-
fold increased burden of large deletions on chromosome 
16p13.11, a region previously associated with other neu-
rodevelopmental disorders. Another recent study observed 
a significantly higher frequency of rare CNVs, especially 
deletions, affecting brain-related genes, in individuals with 
OCD when compared with healthy controls (Grünblatt et 
al., 2017). Additional CNV variants that have been detected 
to date are mostly involved in immune processes and neu-
ronal development (Delorme et al., 2010; Fernandez et al., 
2012; Walitza et al., 2012; Nag et al., 2013; Cappi et al., 2014; 
McGrath et al., 2014; Gazzellone et al., 2016).
A whole exome sequencing study (Cappi et al., 2014) of 
20 OCD cases and their unaffected parents detected an 
increase in de-novo mutation rate relative to the healthy 
controls from the publicly available 1000 Genomes 
Project. The mutations identified in the OCD individu-
als suggested an enrichment of genes involved in immu-
nological systems and the central nervous system.
Pharmacogenetics of antidepressants in obsessive-
compulsive disorder
Pharmacogenetics has become increasingly important in 
the pharmacological treatment of psychiatric disorders 
because only approximately 50% of patients respond 
to psychotropic medications in general. Interindividual 
genetic variations have been the focus of the identifica-
tion of predictors of drug response and tolerability.
Previous pharmacogenomics studies in OCD reported 
trends in known genetic variations across the cytochrome 
P450 liver enzymes, glutamatergic, and serotonergic sys-
tem genes (Zai et al., 2014).
CYP450 is extensively involved in drug metabolism 
that plays a central role in medicine. Many medications 
are not only substrates for these enzymes but may also 
inhibit or induce enzymatic activity. Genetic variations 
encoding CYP450 enzymes can lead to alteration of 
metabolism, which can influence clinical response and 
adverse events of medications (Elliott et al., 2017). There 
are many genes coding for CYP450 enzymes that metab-
olize SSRIs, but only CYP2D6 and CYP2C19 have been 
studied using small sample sizes (Van Nieuwerburgh 
et al., 2009; Müller et al., 2012; Brandl et al., 2014). 
Brandl et al. (2014) has reported that individuals with 
CYP2D6 nonextensive metabolism (intermediate, poor, 
and ultrarapid metabolisms) were found to be associated 
with higher number of antidepressant trials (48 versus 
22% with ≥4 trials; P = 0.007) and greater side effects 
from venlafaxine (P = 0.022).
Psychotropic medications have pharmacodynamic mech-
anism of actions, interacting with various neurotrans-
mitter systems including sertonergic, glutamatergic, and 
dopaminergic systems, which have all been implicated 
in antidepressant treatment response and adverse effects 
in OCD (Zai et al., 2014). Serotonergic genes that have 
been previously examined in OCD include: SLC6A4 and 
its promoter (5-HTTLPR), HTR2A, HTR2C, HTR1B, and 
TPH. However, only one study (Corregiari et al., 2012) 
reported a significant finding between HTR2A rs6305 and 
nonresponders. Real et al. (2010) and Zhang et al. (2015a) 
examined the glutamatergic gene SLC1A1 to prospective 
SSRI response and reported a significant association with 
rs301434 and SSRI nonresponse, and between rs301430 
and fluoxetine response. A recent study detected sig-
nificant associations between SLC1A1 rs2228622 and 
rs3780413 with fluvoxamine response (Abdolhosseinzadeh 
et al., 2019). Five studies, investigating the dopaminergic 
DRD2, DRD4, COMT, and MAOA, have been performed, 
but they were all negative (Zhang et al., 2004; Miguita et al., 
2011; Vulink et al., 2012; Viswanath et al., 2013; Umehara 
et al., 2015) except for COMT rs4680 Met/Met genotype 
with citalopram response (Vulink et al., 2012). Several 
studies conducted in other candidate genes have detected 
inconsistent results (Zai et al., 2014). The first pharmaco-
genetic GWAS of OCD (Qin et al., 2016) was conducted in 
804 OCD cases and detected one significant finding with 
antidepressant response and the DISP1 rs17162912 SNP 
(P = 1.76 × 10–8); however, this finding was not replicated 
in an independent OCD sample (Lisoway et al., 2018). 
Further research is required to clarify the potential roles 
of these genes in OCD pharmacogenetics.
Endophenotype genetics
The use of endophenotypes as a way to ascertain homo-
geneous phenotypes for genetic studies has provided 
important avenue to elucidate the etiology of OCD. The 
search of endophenotypes in the genetics of OCD has 
been generally guided by their strong association with 
OCD, high heritability, and observable similar deficits in 
unaffected relatives (Gottesman and Gould, 2003; Glahn 
et al., 2014). Endophenotypes may be of clinical utility in 
the search for underlying genetic diatheses and thus, for 
informing diagnostic classification and ultimately provid-
ing guidance to treatment management of OCD.
Genetics of cognitive deficits in obsessive-compulsive 
disorder
Deficits across several cognitive domains with inconsist-
ency have been reported in individuals with OCD. The 
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observed cognitive deficits in OCD are mainly within the 
executive function domain (Tükel et al., 2012), cognitive 
inflexibility (Chamberlain et al., 2006; Bradbury et al., 
2011) and motor inhibitory control deficits (Chamberlain 
et al., 2005). Only three genetic studies to date have 
examined the effects of genetic vulnerability to these 
cognitive deficits in OCD (da Rocha et al., 2011; Tükel 
et al., 2012, 2013). The studies examined a functional 
genetic variation within BDNF and COMT in cognitive 
functions of individuals with OCD. The authors observed 
poorer performance of the Trail-Making Test (TMT) 
in OCD COMT rs4680 Met carrier, suggesting that the 
lower activity enzyme with higher level of dopamine in 
the prefrontal cortex may lead to poorer executive func-
tion in patients with OCD (Tükel et al., 2013). Tükel et 
al. (2012) also reported that the BDNF rs6265 Met car-
riers had significantly slower performance on TMT A 
and B and poorer performance on verbal fluency when 
compared with healthy control Met carriers (Tükel et al., 
2012). The other study showed the BDNF rs6265 Met 
carriers exhibited lower performance on decision making 
under ambiguous conditions only (da Rocha et al., 2011) 
but no significant differences in the TMT task perfor-
mance. Replication studies with larger samples and the 
development of a broad cognitive battery with systematic 
and well standardized cognitive tasks that are reliable, 
easy to interpret, and comparable based on modern cog-
nitive neuroscience approaches will be required in order 
to derive more definitive conclusions.
Imaging genetics of obsessive-compulsive disorder
Imaging genetics utilizes neuroimaging and genetics to 
assess the impact of genetic variations on brain function 
and structure. Recently, large international efforts have 
begun to use imaging genetics approach on large sam-
ple sizes (i.e., ENIGMA, IMAGEN, ADNI, CHARGE) 
(Medland et al., 2014; Thompson et al., 2014; Bearden and 
Thompson, 2017; Bogdan et al., 2017). Imaging genetics 
studies in OCD to date have mainly focused on candidate 
genes (Arnold et al., 2009a,b; Scherk et al., 2009; Atmaca 
et al., 2010, 2011; Hesse et al., 2011; Wu et al., 2013; Wolf 
et al., 2014; Gassó et al., 2015; Mas et al., 2016; Ortiz et al., 
2016; Honda et al., 2017). A systematic review (Grünblatt 
et al., 2014) reported that the main genetic pathways 
investigated in OCD were among the commonly studied 
neurotransmitter systems, the serotonergic, glutamater-
gic, and dopaminergic systems. Within the serotonergic 
system, the OFC and the raphe nuclei have been found to 
be associated with the SLC6A4 5-HTTLPR gene variant 
(Grünblatt et al., 2014). A recent study observed a reduc-
tion of gray matter volumes in the right frontal pole in 
OCD L
A
 allele carriers when compared with healthy con-
trols (Honda et al., 2017). With regard to the glutamatergic 
system, the CSTC circuit, OFC, thalamus, and anterior 
cingulate cortex (ACC) have been detected to be asso-
ciated with several gene variations in glutamate-related 
genes (Honda et al., 2017). The increased concentrations 
of choline measured by 1H-MRS in the ACC of individ-
uals with OCD have been associated with SNPs in the 
glutamate receptor AMPA1 gene (GRIA1) (Ortiz et al., 
2016). Mean diffusivity in the right anterior and poste-
rior cerebellar lobes has been observed to be associated 
with the SLC1A1 rs3087879 marker in patients with OCD 
(Gassó et al., 2015). Several studies on dopaminergic loci 
and imaging data have reported a positive association 
between the dopamine transporter gene (SLC6A3) and 
the metabolism of N-acetylaspartate in the putamen as 
measured by MRS (Grünblatt et al., 2014), in addition to 
the mean diffusivity of the white matter in right anterior 
and posterior cerebellar lobes (Gassó et al., 2015).
Given the complexity and heterogeneity of OCD phe-
notype, current efforts have been focused on combining 
polygenic risk scores with neuroimaging, particularly in 
large consortia, in order to overcome ongoing low sta-
tistical power in imaging genetic studies, such as in the 
ENIGMA consortium (Bearden and Thompson, 2017). 
Additional techniques including novel biostatistical 
approaches (Bearden and Thompson, 2017; Bogdan et al., 
2017; Mattingsdal et al., 2013: Meda et al., 2012; Nymberg 
et al., 2013) and machine learning (Mas et al., 2016) have 
been developed for the prediction of diagnosis, progno-
sis, and treatment response.
Epigenetics of obsessive-compulsive disorder
Epigenetics refers to the heritable changes in gene 
expression via DNA methylation or histone modification 
without changes to the underlying DNA sequence – a 
change in phenotype without a change in genotype.
In a genome-wide DNA methylation analysis of blood 
cells from 65 OCD patients and 96 healthy controls, sev-
eral differentially methylated genes have been identified, 
which include previously implicated candidate genes for 
OCD such as BCYRN1, BCOR, FGF13, HLA-DRB1, ARX, 
etc. These results further suggest the important role of 
epigenetic phenomena in the development of OCD (Yue 
et al., 2016). However, these same findings were not repli-
cated in a smaller study that analyzed 14 candidate genes 
including SLC1A1, SLC25A12, GABBR1, GAD1, DLGAP1, 
MOG, BDNF, OLIG2, NTRK2, NTRK3, ESR1, SLC6A4, 
TPH2, and COMT (Nissen et al., 2016). Another study 
observed an increase in the methylation level at the oxy-
tocin receptor (OXTR) gene in patients with OCD than in 
healthy controls and the level of methylation was found 
to be correlated with OCD symptom severity (Cappi et 
al., 2016). Grünblatt et al. (2018) reported a significantly 
higher SLC6A4 DNA methylation levels in pediatric 
OCD patients when compared with controls and adults 
with OCD. Cappi et al. (2016) observed that individuals 
with OCD showed more DNA methylation than healthy 
controls in exons of the oxytocin receptor gene (OXTR) 
using peripheral blood leukocytes.
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Gene x gene and gene x environment interactions
The first family study examining gene–gene interaction 
is the Brazilian collaborative group and they investigated 
the epistatic effect between COMT and MAOA in 783 
OCD trios (Sampaio et al., 2015), which was negative. 
Significant gene–gene interactions have been detected 
between COMT rs362204 and two SNPs across the mono-
amine oxidase B (MAO-B) gene, rs1799836 and rs6651806 
(McGregor et al., 2016).
Heritability estimates of OCD have detected the impor-
tance of specific environmental factors that interact 
closely with genetic vulnerability, which in turn increase 
the risk of developing OCD. A population-based study 
of environmental risk factors for OCD (Brander et al., 
2016a) found that impaired fetal growth, preterm birth, 
breech presentation, Cesarean section, and maternal 
smoking during pregnancy were associated with the sus-
ceptibility of developing OCD (Brander et al., 2016b, 
2017). This study also identified a dose-response rela-
tionship between the environmental exposures and the 
development of OCD. The risk modifier for OCD, group 
A streptococcal infections, have not been consistently 
demonstrated to date (Hoekstra et al., 2013; Brander et 
al., 2016a). A recent systematic review has postulated that 
environmental factors may only increase the OCD risk in 
genetically susceptible individuals (Brander et al., 2016a).
Shared genetic basis with other psychiatric disorders
Multiple cross-disorder genetic studies have revealed 
both shared and distinct genetic basis between OCD and 
several other psychiatric disorders including anorexia 
nervosa (Yilmaz et al., 2018), autistic spectrum disorder 
(Guo et al., 2017), attention deficit hyperactivity disorder 
(Ritter et al., 2017), Tourette disorder (Davis et al., 2013; 
McGrath et al., 2014; Yu et al., 2015; Zilhão et al., 2016), 
and schizophrenia (Costas et al., 2016), suggesting com-
mon biological mechanism across psychiatric disorders 
and common genetic markers causing different psychiat-
ric disorders in general. A recent study by the Brainstorm 
Consortium conducted a collaborative GWAS meta-anal-
ysis for 25 brain disorders including psychiatric and neu-
rological disorders in 265 218 cases and 784 632 controls 
and once again demonstrated significant genetic overlap 
between several different psychiatric disorders including 
the first group with anorexia nervosa, OCD, and schiz-
ophrenia, and the second group with Tourette disorder, 
OCD, and major depressive disorder (Brainstorm et al., 
2018). These cross-disorder studies support an underly-
ing shared genetic mechanism across various psychiatric 
disorders including OCD.
Conclusion and future perspective
OCD is a psychiatric syndrome with diverse and heter-
ogeneous symptom characteristics, complex genetics, 
and neurobiological mechanisms. Individuals with OCD 
often present with varied symptoms but treatment tends 
to be the same, either with the use of an SRI antidepres-
sant, cognitive behavioral therapy, or a combination of 
both. Management of OCD has not provided tremendous 
success given its chronic, persisting, and heterogeneous 
nature. Therefore, improvement in precision medicine 
may enable clinicians to treat each patient with targeted 
therapies in the future.
Existing genomic studies have yielded important data-
sets and interesting findings that will require further 
exploration, in larger and well-characterized OCD sam-
ples. Because of the etiological, neurobiological, and 
therapeutic heterogeneity and complexity of OCD, it is 
not surprising that the identification of specific genetic 
factors has been relatively unproductive thus far. Most 
robust findings have implicated impairment of the 
cortico-striatal function and the glutamatergic neuro-
transmitter system, which have led to preliminary data, 
supporting the use of glutamatergic agents such as rilu-
zole, memantine, N-acetylcysteine, in the treatment of 
OCD (Hirschtritt et al., 2017). However, it has been diffi-
cult to infer or identify from these results a precise patho-
physiological mechanism for OCD or obvious molecular 
targets for novel treatments. The cause of OCD is likely 
a combination of common, rare inherited, and de-novo 
risk variants, suggesting a polygenic model of liability 
(Browne et al., 2014), in addition to nongenetic factors. 
Elucidating the genetic underpinnings of this condition 
has therefore been a major challenge due to the com-
plexity of multifactorial involvements, and will require 
the integration of genomic, epigenomic, and gene-by-en-
vironment information.
In the next several decades, the field of psychiatric genom-
ics will likely expand to involve international collaborative 
efforts, to use new developments in genetic knowledge 
(i.e., regulatory elements) and new advances in genetic 
technology (i.e., high-throughput genomics and biosta-
tistical models), in combination with transcriptomics and 
proteinomics, to gain fresh new insight into the complex 
genetic architecture of OCD. Understanding the underly-
ing biological mechanisms of OCD will hopefully lead to 
the introduction of new treatment strategies for this inca-
pacitating psychiatric disorder. New discoveries certainly 
have the potential to transform the field of psychiatric 
genetics, which is moving along the goal of eventual trans-
lation into clinical practice. These new advances promise 
new understanding and novel avenues for prevention and 
treatment of mental illnesses; but they will also present 
with significant clinical and ethical challenges.
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